Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109795

Variant von Willebrand's Disease: CHARACTERIZATION OF TWO SUBTYPES BY ANALYSIS OF MULTIMERIC COMPOSITION OF FACTOR VIII/VON WILLEBRAND FACTOR IN PLASMA AND PLATELETS

Zaverio M. Ruggeri and Theodore S. Zimmerman

Department of Molecular Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037

Find articles by Ruggeri, Z. in: PubMed | Google Scholar

Department of Molecular Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037

Find articles by Zimmerman, T. in: PubMed | Google Scholar

Published June 1, 1980 - More info

Published in Volume 65, Issue 6 on June 1, 1980
J Clin Invest. 1980;65(6):1318–1325. https://doi.org/10.1172/JCI109795.
© 1980 The American Society for Clinical Investigation
Published June 1, 1980 - Version history
View PDF
Abstract

We have examined the multimeric composition of factor VIII/von Willebrand factor in plasma and platelet lysates by means of sodium dodecyl sulfate agarose electrophoresis followed by staining with 125I-labeled affinity-purified antibody. In normal plasma and platelet lysates, factor VIII/von Willebrand factor displayed 10 distinct multimers that ranged in apparent molecular weight from 0.86 to 9.9 × 106. The molecular weight difference between adjacent bands was 0.8−1.1 × 106. Larger material, not resolved into discrete bands, was also present with an average Mr of 14.5 × 106. Though the dimer (apparent Mr = 0.48 × 106) and the monomer (apparent Mr = 0.28 × 106) generated by reduction of disulfide bonds were readily identified in this system, they were not detected in normal plasma or platelets. No differences were observed between fresh plasma prepared without anticoagulant and fresh or frozen plasma anticoagulated with either citrate or heparin. “Variant” (type II) von Willebrand's disease could be divided into two subtypes. In subtype IIA, factor VIII/von Willebrand factor in plasma consisted predominantly of the five smaller multimers with traces of the sixth and seventh (Mr up to 4.5 × 106). In subtype IIB, all these multimers were easily detected and, in addition, bands of intermediate size (Mr = 8.5 × 106 and smaller) were present. In contrast, the multimeric composition of IIB platelet factor VIII/von Willebrand factor was identical to normal, whereas in subtype IIA the larger multimers were absent from platelets as well as from plasma. In subtype IIB, binding of factor VIII/von Willebrand factor to platelets occurred at lower concentrations of ristocetin than required for normal and multimers of smaller size than in normal bound. On the contrary, in subtype IIA, binding was minimal, as was true of normal factor VIII/von Willebrand factor of equivalent size. Thus, physical as well as functional differences in the two subtypes of variant von Willebrand's disease described suggest that different pathogenetic mechanisms underlie the factor VIII/von Willebrand factor abnormalities in these patients.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1318
page 1318
icon of scanned page 1319
page 1319
icon of scanned page 1320
page 1320
icon of scanned page 1321
page 1321
icon of scanned page 1322
page 1322
icon of scanned page 1323
page 1323
icon of scanned page 1324
page 1324
icon of scanned page 1325
page 1325
Version history
  • Version 1 (June 1, 1980): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts